CRISPR Therapeutics AG Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1.5M | 864K | 889K | 892K | 865K | 35.0M | 602K | 517K |
| Cost of Goods Sold | 50.2M | 59.4M | 64.7M | 49.8M | 57.5M | 0 | 16.0M | 57.0M |
| Gross Profit | -48.8M | -58.5M | -63.8M | -48.9M | -56.6M | 35.0M | -15.4M | -56.5M |
| R&D Expenses | 68.6M | 77.9M | 58.9M | 65.3M | 72.5M | 82.2M | 77.4M | 75.3M |
| Operating Expenses | 81.5M | 96.3M | 68.3M | 84.2M | 91.8M | 99.6M | 94.8M | 94.8M |
| Operating Income | -130.2M | -154.8M | -132.1M | -133.1M | -148.4M | -64.6M | -110.1M | -151.3M |
| Other Income / Gains | 8.2M | 24.8M | 26.2M | -74.2M | 13.5M | 28.0M | 25.1M | 26.1M |
| Net Income | -122.9M | -130.6M | -106.4M | -208.5M | -136.0M | -37.3M | -85.9M | -126.4M |
| EPS (Diluted) | -1.28 | -1.37 | -1.17 | -2.40 | -1.58 | -0.44 | -1.01 | -1.49 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | -33.464 | -67.708 | -71.771 | -54.777 | -65.484 | 1.00 | -25.50 | -109.205 |
| General And Administrative Expenses | 17.2M | 18.4M | 16.9M | 18.9M | 19.3M | 18.1M | 0 | 19.5M |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 17.2M | 18.4M | 16.9M | 18.9M | 19.3M | 18.1M | 17.4M | 19.5M |
| Other Expenses | -4.3M | 0 | -7.6M | 0 | 0 | -691K | 0 | 0 |
| Cost And Expenses | 131.7M | 155.6M | 132.9M | 134.0M | 149.3M | 99.6M | 110.7M | 151.8M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation And Amortization | 4.3M | 5.7M | 4.4M | 4.6M | 4.7M | 4.8M | 4.7M | 4.8M |
| Ebitda | -117.8M | -124.3M | -101.4M | -202.7M | -130.2M | -31.8M | -80.3M | -120.3M |
| Ebitdaratio | -80.777 | -143.91 | -114.048 | -227.194 | -150.464 | -0.908 | -133.434 | -232.642 |
| Operating Income Ratio | -89.333 | -179.125 | -148.548 | -149.183 | -171.588 | -1.845 | -182.94 | -292.573 |
| Income Before Tax | -122.1M | -130.0M | -105.8M | -207.3M | -134.9M | -36.6M | -85.1M | -125.1M |
| Income Before Tax Ratio | -83.739 | -150.462 | -119.035 | -232.351 | -155.939 | -1.046 | -141.306 | -242.014 |
| Income Tax Expense | 839K | 614K | 619K | 1.3M | 1.1M | 700K | 876K | 1.3M |
| Net Income Ratio | -84.315 | -151.172 | -119.731 | -233.799 | -157.221 | -1.066 | -142.761 | -244.503 |
| Epsdiluted | -1.28 | -1.37 | -1.17 | -2.40 | -1.58 | -0.44 | -1.01 | -1.49 |
| Weighted Average Shs Out | 96.1M | 89.9M | 91.3M | 87.1M | 85.9M | 85.5M | 85.2M | 84.9M |
| Weighted Average Shs Out Dil | 96.1M | 89.9M | 91.3M | 87.1M | 85.9M | 85.5M | 85.2M | 84.9M |